Summary: What the Research Tells Us Long-term Efficacy and the Yoyo Effect of GLP-1 Agonists (Saxenda, Wegovy, Ozempic, Mounjaro) One of the most important concerns in any weight loss journey is whether the results can be sustained or whether the dreaded yoyo effect (regaining the lost weight) will occur
Las guas de la ADA recomiendan reevaluar la terapia si no se alcanzan los objetivos glucmicos despus de 3 meses de tratamiento ptimo
15.6 2.6 mpH/min
Most adults (70%) who have taken GLP-1 drugs say their insurance covered at least a part of the cost of these drugs, including about half (48%) who say their insurance covered part of the cost of these drugs and about one in five (22%) who say their insurance covered all of the cost
New Drugs, Comparative Analysis, and Combination/Multidrug Therapy Other new drugs are under study, such as new oral GLP-1RAs (e.g., danuglipron or orforglipron) or dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist or triple agonists, glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon agonists (retatrutide-LY3437943), which can expand the arsenal of treatment opportunities in the future
reduce visceral, subcutaneous and liver fat contents
.png)
